Wellcome Trust
VC Fund
London, United Kingdom
Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.
- Total investments:
- 125
- Last investment:
- Lead investor:
- 41%
- Fund size:
- $319M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Wellcome Trust invests in
Stages Wellcome Trust invests in
Countries Wellcome Trust invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Grant
- $1.6M–$10M
- Series C
- $10M–$127M
Investment Focus
Industry
- Biotechnology 55 (44%)
- Health Care 42 (34%)
- Medical 20 (16%)
- Pharmaceutical 20 (16%)
- Therapeutics 17 (14%)
Stage
- Grant 24 (19%)
- Series C 18 (14%)
- Funding Round 16 (13%)
- Series B 14 (11%)
- Series A 8 (6%)
Country
- United States 34 (27%)
- United Kingdom 27 (22%)
- France 3 (2%)
- Germany 3 (2%)
- Australia 3 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Dame Davies
Board of Governors
|
Board of Governors | Total investments: 0 | Find email | |
Ed Whiting
Director of Strategy
|
Director of Strategy | Total investments: 0 | Find email | |
Geoff Love
Head of Venture Capital and Equity Long/Short Investments
|
Head of Venture Capital and Equity Long/Short Investments | Total investments: 0 | Find email | |
James Thomas
Chief Technology Officer
|
Chief Technology Officer | Total investments: 0 | Find email | |
Jeremy Farrar
Director
|
Director | Total investments: 1 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ineffable Intelligence
|
Ineffable Intelligence develops machine learning systems that learn through interaction and experience. The company works on reinforcement learning approaches that allow models to improve by trial and error rather than relying on large human-generated datasets. Its core work centers on building a “superlearner,” a system designed to generateknowledge and skills by engaging with simulated or real environments.The organization develops algorithms and computational frameworks that support autonomous learning, experimentation, and decision-making processes. Its efforts involve designing AI models that can adapt, refine behavior, and solve complex problems through continuous feedback loops. The company’s research aims to expand how AI systems acquire knowledge and apply it across different domains. | $1.1B / Seed / Apr 27, 2026 | |
Lario Therapeutics
|
Lario Therapeutics is a biopharmaceutical firm that develops precision therapeutics for epilepsy and neurological disorders. | $2.4M / Grant / Feb 19, 2026 | |
Wysa
|
Wysa provides a mental health wellness platform to help manage stress from health anxiety behavior of employees and patients. Wysa provides early intervention to high-risk groups through an AI chatbot, a library of evidence-based self-help tools, and messaging-based support from human therapists. It blends AI-guided listening with professionalexpert support. | $7.3M / Grant / Feb 02, 2026 | |
System
|
System helps teams discover data, share insights, and build knowledge. | $6.5M / Grant / Dec 16, 2025 | |
Medicines and Healthcare products Regulatory Agency
|
The Medicines and Healthcare products Regulatory Agency, an executive agency of the Department of Health, exists to enhance and improve the health of millions of people every day through the effective regulation of medicines and medical devices, underpinned by science and research. | $2.6M / Grant / Nov 27, 2025 | |
National Institute for Health and Care Excellence (NICE)
|
NICE was originally set up in 1999 as the National Institute for Clinical Excellence, a special health authority, to reduce variation in the availability and quality of NHS treatments and care.In 2005, after merging with the Health Development Agency, we began developing public health guidance to help prevent ill health and promote healthierlifestyles. Our name changed to the National Institute for Health and Clinical Excellence.In April 2013 we were established in primary legislation, becoming a Non Departmental Public Body (NDPB) and placing us on a solid statutory footing as set out in the Health and Social Care Act 2012. At this time we took on responsibility for developing guidance and quality standards in social care, and our name changed once more to reflect these new responsibilities.As an NDPB, we are accountable to our sponsor department, the Department of Health, but operationally we are independent of government. Our guidance and other recommendations are made by independent committees. The NICE Board sets our strategic priorities and policies, but the day to day decision-making is the responsibility of our Senior Management Team (SMT).The way NICE was established in legislation means that our guidance is officially England-only. However, we have agreements to provide certain NICE products and services to Wales, Scotland and Northern Ireland. Decisions on how our guidance applies in these countries are made by the devolved administrations, who are often involved and consulted with in the development of NICE guidance. | $2.6M / Grant / Nov 27, 2025 | |
The Academy of Medical Sciences
|
The Academy of Medical Sciences is a biomedical and research center that helps improve people's health. They provide unique financing and professional development opportunities for researchers. They assist researchers in collaborating with academics, the general public, policymakers, and industry to make the maximum impact on health. | $35.8M / Grant / Nov 24, 2025 | |
Biocentis
|
We are a biotech company re-shaping the future of insect control with a unique technology platform that combines environmental sustainability and unprecedented effectiveness.As a spin-out from Imperial College London, a global leader in genetic pest control, we build upon over 20 years of research by our scientific founders, whose pioneering workin genetic control technologies has garnered global recognition.With a presence in the UK and Italy, we leverage the experience of a diverse and accomplished team from 7 countries with unparalleled experience in the scientific and technological fields and an outstanding track record in company building and management. | $5.9M / Grant / Nov 18, 2025 | |
BioVersys
|
Bioversys AG is a biopharmaceutical company located in Basel that focuses on research and development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and restore the efficacy of approved antibiotics. Their focus is on creating therapies to combat multidrug-resistant (MDR) bacterial infections, a major globalhealth issue. BioVersys’ proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform is designed to identify new treatments by inhibiting bacterial resistance mechanisms, thereby making antibiotics more effective. | $17.4M / Grant / Nov 10, 2025 | |
Cultivarium
|
Cultivarium develops open-source tools for life scientists to expand access to novel microorganisms and research. | $10M / Grant / Apr 24, 2025 | |
| See all 125 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Wellcome Trust invest in?
Wellcome Trust invests primarily in Biotechnology, Health Care and Medical startups, most often at Grant and Series C stage. Most of the 125 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Wellcome Trust's check size?
Wellcome Trust typically joins rounds of $1.6M–$10M at Grant and $10M–$127M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Wellcome Trust participates in.
How do I contact Wellcome Trust?
Public channels for Wellcome Trust include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Wellcome Trust?
The team at Wellcome Trust includes Dame Davies (Board of Governors), Ed Whiting (Director of Strategy) and Geoff Love (Head of Venture Capital and Equity Long/Short Investments), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
